{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T17:20:27Z","timestamp":1771003227811,"version":"3.50.1"},"reference-count":32,"publisher":"Japan Society for Clinical Immunology","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Jpn. J. Clin. Immunol.","Jpn.J.clin.Immun"],"published-print":{"date-parts":[[2013]]},"DOI":"10.2177\/jsci.36.156","type":"journal-article","created":{"date-parts":[[2013,6,29]],"date-time":"2013-06-29T22:45:54Z","timestamp":1372545954000},"page":"156-161","source":"Crossref","is-referenced-by-count":3,"title":["Resolving factors of inflammation\u2014a bridge between Innate immunity and Adaptive immunity","\u708e\u75c7\u53ce\u675f\u56e0\u5b50\u2014\u81ea\u7136\u514d\u75ab\u304b\u3089\u7372\u5f97\u514d\u75ab\u3078\u306e\u6a4b\u6881\u2014"],"prefix":"10.2177","volume":"36","author":[{"given":"Hirahito","family":"ENDO","sequence":"first","affiliation":[{"name":"Division of Rheumatology, Department of Internal Medicine, Toho University"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"972","reference":[{"key":"1","unstructured":"1) Serhan CN. : Lipoxins and aspirin-triggered 15-epi-lipoxins are the first lipid mediators of endogenous anti-inflammation and resolution. <i>Prostaglandins Leukot Essent Fatty Acids<\/i>, <b>73<\/b> : 141-162, 2005."},{"key":"2","unstructured":"2) Serhan CN, Krishnamoorthy S, Recchiuti A, et al. : Novel anti-inflammatory-pro-resolving mediators and their receptors. <i>Curr Top Med Chem<\/i>., <b>11<\/b> : 629-647, 2011."},{"key":"3","unstructured":"3) Lee HN, Surh YJ. : Therapeutic potential of resolvins in the prevention and treatment of inflammatory disorders. <i>Biochem Pharmacol<\/i>., <b>15<\/b> : 1340-1350, 2012."},{"key":"4","unstructured":"4) Chiang N, Serhan CN, Dahl&eacute;n SE, et al. : The lipoxin receptor ALX : potent ligand-specific and stereoselective actions in vivo. <i>Pharmacol Rev<\/i>., <b>58<\/b> : 463-487, 2006."},{"key":"5","doi-asserted-by":"crossref","unstructured":"5) Ernet MC, Sinal CJ : Chemerin ; at the cross road of Inflammation and obesity, <i>Trens Endocrinol Metabolism<\/i>, <b>21<\/b> : 660-667, 2011.","DOI":"10.1016\/j.tem.2010.08.001"},{"key":"6","unstructured":"6) Renda G, Zurro M, Romano M, et al. : Aspirin-triggered lipoxin in patients treated with aspirin and selective vs. nonselective COX-2 inhibitors. <i>Br J Clin Pharmacol<\/i>., <b>69<\/b> : 303-306, 2010."},{"key":"7","doi-asserted-by":"crossref","unstructured":"7) Wittamer V, Bondue B, Guillabert A., et al. : Neutrophil-mediated maturation of chemerin : a bridge between innate immunity and adaptive immunity, <i>J Immunol<\/i>, <b>175<\/b> : 487-493, 2005.","DOI":"10.4049\/jimmunol.175.1.487"},{"key":"8","unstructured":"8) Hashimoto A, Hayashi I, Murakami Y. et al. : Antiinflammatory mediator lipoxin A<sub>4<\/sub> and its receptor in synovitis of patients with rheumatoid arthritis. <i>J Rheumatol<\/i>. <b>34<\/b> : 2144-2153, 2007."},{"key":"9","doi-asserted-by":"crossref","unstructured":"9) Chan MM, Moore AR. Resolution of inflammation in murine autoimmune arthritis is disrupted by cyclooxygenase-2 inhibition and restored by prostaglandin E2-mediated lipoxin A<sub>4<\/sub> production. <i>J Immunol<\/i>. <b>184<\/b> : 6418-6426, 2010.","DOI":"10.4049\/jimmunol.0903816"},{"key":"10","unstructured":"10) Kr&ouml;nke G, Katzenbeisser J, Uderhardt S, et al. : 12\/15-lipoxygenase counteracts inflammation and tissue damage in arthritis. <i>J Immunol<\/i>., <b>183<\/b> : 3383-3389, 2009."},{"key":"11","unstructured":"11) Kowal-Bielecka O, Kowal K, Distler O, et al. : Cyclooxygenase- and lipoxygenase-derived eicosanoids in bronchoalveolar lavage fluid from patients with scleroderma lung disease : an imbalance between proinflammatory and antiinflammatory lipid mediators. <i>Arthritis Rheum<\/i>., <b>52<\/b> : 3783-3791, 2005."},{"key":"12","unstructured":"12) Kowal-Bielecka O, Kowal K, Distler O, et al. : Mechanisms of Disease : leukotrienes and lipoxins in scleroderma lung disease-insights and potential therapeutic implications. <i>Nat Clin Pract Rheumatol<\/i>., <b>3<\/b> : 43-51, 2007."},{"key":"13","unstructured":"13) Martins V, Valen&ccedil;a SS, Farias-Filho FA, et al. : ATLa, an aspirin-triggered lipoxin A<sub>4<\/sub> synthetic analog, prevents the inflammatory and fibrotic effects of bleomycin-induced pulmonary fibrosis. <i>J Immunol<\/i>, <b>182<\/b> : 5374-5381, 2009."},{"key":"14","unstructured":"14) Kebir D, J&oacute;zsef L, Pan W, et al. : 15-epi-lipoxin A<sub>4<\/sub> inhibits myeloperoxidase signaling and enhances resolution of acute lung injury. <i>Am J Respir Crit Care Med<\/i>. <b>180<\/b> : 311-319, 2009."},{"key":"15","unstructured":"15) Wu SH, Liao PY, Yin PL, et al. : Elevated expressions of 15-lipoxygenase and lipoxin A<sub>4<\/sub> in children with acute poststreptococcal glomerulonephritis. <i>Am J Pathol<\/i>. <b>174<\/b> : 115-122, 2009."},{"key":"16","doi-asserted-by":"crossref","unstructured":"16) Das UN. Lipoxins as biomarkers of lupus and other inflammatory conditions. <i>Lipids Health Dis<\/i>. <b>15<\/b> : 76, 2011.","DOI":"10.1186\/1476-511X-10-76"},{"key":"17","unstructured":"17) Yamaguchi H, Higashi N, Mita H, et al. : Urinary concentrations of 15-epimer of lipoxin A(4) are lower in patients with aspirin-intolerant compared with aspirin-tolerant asthma. <i>Clin Exp Allergy<\/i>., <b>41<\/b> : 1711-1718, 2011."},{"key":"18","unstructured":"18) Hao H, Liu M, Wu P, et al. : Lipoxin A<sub>4<\/sub> and its analog suppress hepatocellular carcinoma via remodeling tumor microenvironment. <i>Cancer Lett<\/i>., <b>309<\/b> : 85-94, 2011."},{"key":"19","unstructured":"19) Macdonald LJ, Boddy SC, Denison FC, et al. : A role for lipoxin A<sub>4<\/sub> as an anti-inflammatory mediator in the human endometrium. <i>Reproduction<\/i>., <b>142<\/b> : 345-352, 2011."},{"key":"20","unstructured":"20) Pajdo R, Brzozowski T, Szlachcic A, et al. : Lipoxins, the novel mediators of gastroprotection and gastric adaptation to ulcerogenic action of aspirin. <i>Curr Pharm Des<\/i>., <b>17<\/b> : 1541-1551, 2011."},{"key":"21","unstructured":"21) Van Dyke TE. : Proresolving lipid mediators : potential for prevention and treatment of periodontitis. <i>J Clin Periodontol<\/i>., <b>38<\/b>(511) : 119-125, 2011."},{"key":"22","unstructured":"22) Ho KJ, Spite M, Owens CD, et al. : Aspirin-triggered lipoxin and resolvin E<sub>1<\/sub> modulate vascular smooth muscle phenotype and correlate with peripheral atherosclerosis. <i>Am J Pathol<\/i>., <b>177<\/b> : 2116-2123, 2011."},{"key":"23","unstructured":"23) Kaneko K, Miyabe Y, Takayasu A, et al. : Chemerin activates fibroblast-like synoviocytes in patients with rheumatoid arthritis. <i>Arthritis Res Ther<\/i>. <b>13<\/b> : R158. doi : 10.1186\/ar3475, 2011."},{"key":"24","unstructured":"24) Berg V, Sveinbj&ouml;rnsson B, Bendiksen S, et al. : Human articular chondrocytes express Chem R23 and chemerin ; Chem R23 promotes inflammatory signalling upon binding the ligand chemerin (21-157). <i>Arthritis Res Ther<\/i>. <b>12<\/b> : R228. doi : 10.1186\/ar3215, 2010."},{"key":"25","unstructured":"25) Luangsay S, Wittamer V, Bondue B, et al. : Mouse Chem R23 is expressed in dendritic cell subsets and macrophages, and mediates an anti-inflammatory activity of chemerin in a lung disease model. <i>J Immunol<\/i>., <b>183<\/b> : 6489-6499, 2009."},{"key":"26","unstructured":"26) Demoor T, Bracke KR, Dupont LL, et al. : The role of Chem R23 in the induction and resolution of cigarette smoke-induced inflammation. <i>J Immunol<\/i>., <b>186<\/b> : 5457-5467, 2011."},{"key":"27","unstructured":"27) Bondue B, Vosters O, de Nadai P, et al. : Chem R23 dampens lung inflammation and enhances anti-viral immunity in a mouse model of acute viral pneumonia. <i>PLoS Pathog<\/i>. : e1002358. doi : 10.1371\/journal.ppat.1002358, 2011"},{"key":"28","unstructured":"28) Albanesi C, Scarponi C, Pallotta S, et al. : Chemerin expression marks early psoriatic skin lesions and correlates with plasmacytoid dendritic cell recruitment. <i>J Exp Med<\/i>. <b>16<\/b> : 249-258, 2009."},{"key":"29","unstructured":"29) De Palma G, Castellano G, Del Prete A. et al. : The possible role of Chem R23\/Chemerin axis in the recruitment of dendritic cells in lupus nephritis. <i>Kidney Int<\/i>., <b>79<\/b> : 1228-1235, 2011."},{"key":"30","unstructured":"30) Lin X, Tang X, Jiang Q, et al. : Elevated serum chemerin levels are associated with the presence of coronary artery disease in patients with type 2 diabetes. <i>Clin Lab<\/i>. <b>58<\/b> : 539-544, 2012."},{"key":"31","unstructured":"31) Rhee EJ. Chemerin : A Novel Link between Inflammation and Atherosclerosis? <i>Diabetes Metab J.<\/i>, <b>35<\/b> : 216-218, 2011."},{"key":"32","unstructured":"32) Serhan CN, Savill J. : Resolution of inflammation : the beginning programs the end. <i>Nat Immunol<\/i>., <b>6<\/b> : 1191-1197, 2005."}],"container-title":["Japanese Journal of Clinical Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jsci\/36\/3\/36_156\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,20]],"date-time":"2021-05-20T04:51:45Z","timestamp":1621486305000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jsci\/36\/3\/36_156\/_article\/-char\/ja\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013]]},"references-count":32,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2013]]}},"URL":"https:\/\/doi.org\/10.2177\/jsci.36.156","relation":{},"ISSN":["0911-4300","1349-7413"],"issn-type":[{"value":"0911-4300","type":"print"},{"value":"1349-7413","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013]]}}}